Title Details

Novartis Foundation Symposium 262 - Biology ofIGF-1 - Its Interaction with Insulin in Health and Malignant States
Buy Rights Online Buy Rights

Rights Contact Login For More Details

  • Wiley

More About This Title Novartis Foundation Symposium 262 - Biology ofIGF-1 - Its Interaction with Insulin in Health and Malignant States

  • English

English

An invaluable book containing a series of interdisciplinary discussions between clinical and basic scientists.  Biology of IGF-1: Its interaction with insulin and health and malignant states focuses on key issues such as:
  • the definition of danger zones
  • the development of methods for early recognition of malignant states linked to IGF-1 and/or insulin
  • possible approaches to preventative intervention
  • the relevance in this field of research to the development of novel therapeutic approaches to treating certain cancers.
  • English

English

The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.
  • English

English

Chair's Introduction (Leroith).

Circulating IGF-I and its role in cancer: lessons from the IGF-1 gene-deletion (LID) mouse (Yakar et al).

Physiology of the IGF system (Holly).

Molecular basis of insulin action (Zick).

IGF-1 and insulin as growth hormones (Laron).

Insulin-like growth factors and neoplasia (Pollak).

Loss of IGF2 imprinting: mechanisms and consequences (Ohlsson).

Insulin and IGF-1 receptor trafficking and sginalling (Foti et al).

The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb (Nobukini and Thomas).

Structural biology of insulin and IGF-1 receptors (De Meyts et al).

Genetic blockade of the insulin-like growth factor-I receptor for human malignancy (Adachi et al).

IGF-1 and prostate cancer (Roberts Jr.).

IGF-1 and breast cancer (Lonning and Helle).

IGFBPs and cancer (Fang et al).

The IGF receptor as anti-cancer treatment target (Macaulay).

Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence (Kaaks).

Final discussion.

Index of contributors.

Subject index.

loading